Cite

HARVARD Citation

    Flinn, I. et al. (n.d.). Duvelisib, an oral dual PI3K‐δ, γ inhibitor, shows clinical activity in indolent non‐Hodgkin lymphoma in a phase 1 study. American journal of hematology. 93 (11), pp. 1311-1317. [Online]. 
  
Back to record